Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kodiak Sciences Inc.    KOD

KODIAK SCIENCES INC.

(KOD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
158.54(c) 164.47(c) 158.6(c) 158.02(c) 164.33(c) Last
279 040 252 491 272 291 193 351 170 625 Volume
-2.35% +3.74% -3.57% -0.37% +3.99% Change
More quotes
Financials (USD)
Sales 2020 17,9 M - -
Net income 2020 -126 M - -
Net cash position 2020 739 M - -
P/E ratio 2020 -61,1x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -222 M - -
Net cash position 2021 728 M - -
P/E ratio 2021 -37,1x
Yield 2021 -
Capitalization 8 277 M 8 277 M -
EV / Sales 2020 422x
EV / Sales 2021 -
Nbr of Employees 62
Free-Float 83,5%
More Financials
Company
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic... 
More about the company
Notations Surperformance© of Kodiak Sciences Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about KODIAK SCIENCES INC.
01/05KODIAK SCIENCES : to Present at the J.P. Morgan Healthcare Conference
PR
2020KODIAK SCIENCES : Berenberg Starts Kodiak Sciences at Buy With $156 Price Target
MT
2020KODIAK SCIENCES : UBS Starts Kodiak Sciences at Buy With $170 Price Target
MT
2020KODIAK SCIENCES : Citigroup Starts Kodiak Sciences at Neutral With $134 Price Ta..
MT
2020JPMorgan Downgrades Kodiak Sciences to Neutral From Overweight; Price Target ..
MT
2020Kodiak Sciences Raises $645 Million in Public Offering
MT
2020KODIAK SCIENCES : Announces Closing of $645.0 Million Public Offering of Common ..
PR
2020CLOSE UPDATE : Stocks End Lower as Rising COVID-19 Cases Offset Vaccine Optimism
MT
2020KODIAK SCIENCES INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
2020UPDATE : Kodiak Sciences Prices $560.9 Million Public Share Offering; Shares Up ..
MT
2020MIDDAY REPORT : Wall Street Edges Higher on Vaccine Breakthrough
MT
2020Kodiak Sciences Prices $560.9 Million Public Share Offering
MT
2020KODIAK SCIENCES : Announces Pricing of $560.9 Million Public Offering of Common ..
PR
2020Kodiak Sciences Kicks Off $400 Million Common Stock Offering; Shares Down Aft..
MT
2020KODIAK SCIENCES : Announces Proposed Offering of Common Stock
PR
More news
News in other languages on KODIAK SCIENCES INC.
2020Lonza va soutenir Kodiak dans la production d'un médicament ophtalmique
2020Lonza baut Biokonjugationsanlage für Kodiak Sciences
More news
Analyst Recommendations on KODIAK SCIENCES INC.
More recommendations
Chart KODIAK SCIENCES INC.
Duration : Period :
Kodiak Sciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KODIAK SCIENCES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 124,91 $
Last Close Price 164,33 $
Spread / Highest target 3,45%
Spread / Average Target -24,0%
Spread / Lowest Target -68,4%
EPS Revisions
Managers and Directors
NameTitle
Victor Perlroth Chairman & Chief Executive Officer
John Borgeson CFO, Principal Accounting Officer & Senior VP
Jason S. Ehrlich Chief Medical & Development Officer
Sinette Heys Vice President-Clinical Operations
Felix James Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KODIAK SCIENCES INC.11.86%8 277
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148